(Total Views: 277)
Posted On: 01/09/2017 11:42:42 AM
Post# of 72447
No problem. About P,
Near-Term Value Drivers
• 2Q 2017 – Phase 2b Interim Data
• 3Q 2017 – Phase 2b Complete Top-line Data
• 4Q 2017 – End-of-Phase 2 Meeting with FDA
Broader Context
• Big Pharma Recognizes Value of Safe, Effective Oral Psoriasis Drug
• Cellceutix Actively Discussing Partnerships for Late-Stage Studies
• Targeting NDA Submission to FDA in 4Q 2019
2017 Goals = A Focus On Partnering Opportunities
Successfully Complete
• Phase 2b Trial of Prurisol for Psoriasis
• Phase 2a Trial of Brilacidin for UP/UPS (IBD)
• Phase 2 Trial of Brilacidin for Oral Mucositis
• Phase 2a Trial of Kevetrin for Ovarian Cancer
• FDA Meetings
- EoP2 for Psoriasis
- SPA for Brilacidin in ABSSSI
Meeting 2017 Milestones Sets the Stage to Potentially Initiate 5 Registration Studies in 2018!
Near-Term Value Drivers
• 2Q 2017 – Phase 2b Interim Data
• 3Q 2017 – Phase 2b Complete Top-line Data
• 4Q 2017 – End-of-Phase 2 Meeting with FDA
Broader Context
• Big Pharma Recognizes Value of Safe, Effective Oral Psoriasis Drug
• Cellceutix Actively Discussing Partnerships for Late-Stage Studies
• Targeting NDA Submission to FDA in 4Q 2019
2017 Goals = A Focus On Partnering Opportunities
Successfully Complete
• Phase 2b Trial of Prurisol for Psoriasis
• Phase 2a Trial of Brilacidin for UP/UPS (IBD)
• Phase 2 Trial of Brilacidin for Oral Mucositis
• Phase 2a Trial of Kevetrin for Ovarian Cancer
• FDA Meetings
- EoP2 for Psoriasis
- SPA for Brilacidin in ABSSSI
Meeting 2017 Milestones Sets the Stage to Potentially Initiate 5 Registration Studies in 2018!
(1)
(0)
